Post
sridharbalakrishnan
SHILPAMED
Shilpa: Biologics will be big growth driver for the company over next 3-5 years. They have also started focusing on India with FTF products, something similar to what Ajanta did. Aggressively filing products in matured markets and this should also support growth. On CRAMs, although they didn't speak a lot, oncology is the area of focus.
Sep 12 5:37 PM
· View Votes
NSE:SHILPAMED price when posted: 581